FAQ: Describe the IL23/IL17 axis
GHAPPcast12 Dec 2024

FAQ: Describe the IL23/IL17 axis

Thank you to Johnson & Johnson for your support of this FAQ Video Module.

Welcome to this FAQ video module, proudly supported by Johnson & Johnson. In this educational session, Erica Heagy, NP, from Alaska Digestive and Liver Disease, explores the IL-23/IL-17 axis, a crucial pathway in the pathogenesis of inflammatory bowel disease (IBD), psoriasis, psoriatic arthritis, multiple sclerosis, and other immune-mediated disorders.

The IL-23 cytokine plays a pivotal role in promoting Th17 cell differentiation, which in turn produces pro-inflammatory cytokines like IL-17A, IL-17F, tumor necrosis factor (TNF), and IL-6. IL-17, a key driver of chronic inflammation, is overexpressed in patients with autoimmune diseases, contributing to tissue damage, immune dysregulation, and inflammation. These effects are particularly evident in conditions such as Crohn’s disease, ulcerative colitis, and psoriatic arthritis, making the IL-23/IL-17 axis a major target for emerging biologic therapies.

Therapeutic strategies that block IL-23 or its receptor have been FDA-approved for treating psoriasis, psoriatic arthritis, and IBD. By inhibiting this inflammatory pathway, these treatments help reduce disease progression, alleviate symptoms, and improve patient outcomes. Understanding this mechanism is essential for healthcare providers seeking optimized, targeted treatment options for their patients.

For more information on IL-23-targeted therapies and advances in gastroenterology, hepatology, and immune-mediated disease treatment, visit GHAPP.org or download the GHAPP ACE mobile app on Android or IOS. Stay connected with us on LinkedIn, YouTube, X (formerly Twitter), and Instagram for expert insights and updates.

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(161)

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this podcast episode. In this GHAPP podcast, host Christina Hanson, FNP, welcomes Janet Gripshover, DNP, FNP-BC, MBA, for a practical discussion on recognizing ...

18 Aug 48min

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

FAQ: Counseling Patients on Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module.In this FAQ video module, Natalie Oliver, PA-C, discusses how healthcare professionals can counsel patients and caregivers about overt hep...

11 Aug 4min

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy

Thank you to Salix for their support on this FAQ video module. In this FAQ video module, Samantha Ramirez, NP-C, discusses how healthcare professionals can identify and diagnose overt hepatic encephal...

4 Aug 2min

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Subgroup Analysis: Differences in Maintenance Dosing For UC and CD

Thank you to Johnson & Johnson for their support on this podcast episode. In this GHAPP podcast, Amy Stewart, NP, of Capital Digestive Care, introduces a practical inflammatory bowel disease discussio...

23 Juli 7min

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC

Thank you to AbbVie for their support of this Medication Review Video Module.In this medication review, Melissa Ferrari, PA, and Jennifer Hamilton, MSPAS, PA-C, provide a comprehensive overview of the...

30 Juni 17min

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease

Thank you to AbbVie for their support on this Medication Review Video Module. In this medication review, Sharon Dudley-Brown, CRNP, PhD from Johns Hopkins University and Angelina Collins, MSN, ANP-BC,...

9 Juni 12min

FAQ: QUASAR Long Term Extension Interim Analysis

FAQ: QUASAR Long Term Extension Interim Analysis

Thank you to Johnson & Johnson for their support on this FAQ Video Module. In this educational video, Jamie Brogan, APRN, from Northwestern Medicine, reviews the latest QUASAR long-term extension data...

2 Juni 4min

Medication Review: Guselkumab IV vs SC Formulation

Medication Review: Guselkumab IV vs SC Formulation

Thank you to Johnson & Johnson for their support on this Medication Review Video Module. In this quick educational video, Angelina Collins, NP, from the University of California San Diego Inflammatory...

28 Maj 3min

Populärt inom Hälsa

somna-med-henrik
rss-bara-en-till-om-beroende-medberoende
rss-jossan-nina
bullfika
rss-vuxna-pa-latsas
inga-beiga-morsor
not-fanny-anymore
johannes-hansen-podcast
angestpodden
sexnoveller-deluxe
sova-med-dan-horning
rss-viktmedicinpodden
rss-hos-psykologen
halsoveckan-by-tyngre
sa-in-i-sjalen
rss-traningsklubben
hacka-livet
tyngre-radio
rss-angra-inget-3
rss-basta-livet